Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 May 18;82(12):1932–1937. doi: 10.1054/bjoc.2000.1167

P53 germline mutations in childhood cancers and cancer risk for carrier individuals

A Chompret 1,3, L Brugières 1, M Ronsin 2, M Gardes 2, F Dessarps-Freichey 2, A Abel 1,3, D Hua 3, L Ligot 3, M-G Dondon 3, B Bressac-de Paillerets 4, T Frébourg 5, J Lemerle 1, C Bonaïti-Pellié 3, J Feunteun 2
PMCID: PMC2363254  PMID: 10864200

Abstract

The family history of cancer in children treated for a solid malignant tumour in the Paediatric Oncology Department at Institute Gustave-Roussy, has been investigated. In order to determine the role of germline p53 mutations in genetic predisposition to childhood cancer, germline p53 mutations were sought in individuals with at least one relative (first- or second-degree relative or first cousin) affected by any cancer before 46 years of age, or affected by multiple cancers. Screening for germline p53 mutation was possible in 268 index cases among individuals fulfilling selection criteria. Seventeen (6.3%) mutations were identified, of which 13 were inherited and four were de novo. Using maximum likelihood methods that incorporate retrospective family data and correct for ascertainment bias, the lifetime risk of cancer for mutation carriers was estimated to be 73% for males and nearly 100% for females with a high risk of breast cancer accounting for the difference. The risk of cancer associated with such mutations is very high and no evidence of low penetrance mutation was found. These mutations are frequently inherited but de novo mutations are not rare. © 2000 Cancer Research Campaign

Keywords: germline, p53 mutation, cancer risk

Full Text

The Full Text of this article is available as a PDF (64.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birch J. M., Hartley A. L., Tricker K. J., Prosser J., Condie A., Kelsey A. M., Harris M., Jones P. H., Binchy A., Crowther D. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994 Mar 1;54(5):1298–1304. [PubMed] [Google Scholar]
  2. Brugières L., Gardes M., Moutou C., Chompret A., Meresse V., Martin A., Poisson N., Flamant F., Bonaïti-Pellié C., Lemerle J. Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res. 1993 Feb 1;53(3):452–455. [PubMed] [Google Scholar]
  3. Eeles R. A. Germline mutations in the TP53 gene. Cancer Surv. 1995;25:101–124. [PubMed] [Google Scholar]
  4. Eeles R. A., Warren W., Knee G., Bartek J., Averill D., Stratton M. R., Blake P. R., Tait D. M., Lane D. P., Easton D. F. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene. 1993 May;8(5):1269–1276. [PubMed] [Google Scholar]
  5. Felix C. A., Strauss E. A., D'Amico D., Tsokos M., Winter S., Mitsudomi T., Nau M. M., Brown D. L., Leahey A. M., Horowitz M. E. A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene. 1993 May;8(5):1203–1210. [PubMed] [Google Scholar]
  6. Flaman J. M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P., Sappino A. P., Limacher I. M., Bron L., Benhattar J. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3963–3967. doi: 10.1073/pnas.92.9.3963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Frebourg T., Barbier N., Yan Y. X., Garber J. E., Dreyfus M., Fraumeni J., Jr, Li F. P., Friend S. H. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet. 1995 Mar;56(3):608–615. [PMC free article] [PubMed] [Google Scholar]
  8. Garber J. E., Goldstein A. M., Kantor A. F., Dreyfus M. G., Fraumeni J. F., Jr, Li F. P. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 1991 Nov 15;51(22):6094–6097. [PubMed] [Google Scholar]
  9. Gutiérrez M. I., Bhatia K. G., Barreiro C., Spangler G., Schvartzmann E., Muriel F. S., Magrath I. T. A de novo p53 germline mutation affecting codon 151 in a six year old child with multiple tumors. Hum Mol Genet. 1994 Dec;3(12):2247–2248. doi: 10.1093/hmg/3.12.2247. [DOI] [PubMed] [Google Scholar]
  10. Ishioka C., Frebourg T., Yan Y. X., Vidal M., Friend S. H., Schmidt S., Iggo R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet. 1993 Oct;5(2):124–129. doi: 10.1038/ng1093-124. [DOI] [PubMed] [Google Scholar]
  11. Jolly K. W., Malkin D., Douglass E. C., Brown T. F., Sinclair A. E., Look A. T. Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene. 1994 Jan;9(1):97–102. [PubMed] [Google Scholar]
  12. Knudson A. G., Jr Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971 Apr;68(4):820–823. doi: 10.1073/pnas.68.4.820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kony S. J., de Vathaire F., Chompret A., Shamsaldim A., Grimaud E., Raquin M. A., Oberlin O., Brugières L., Feunteun J., Eschwège F. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet. 1997 Jul 12;350(9071):91–95. doi: 10.1016/S0140-6736(97)01116-1. [DOI] [PubMed] [Google Scholar]
  14. Le Bihan C., Bonaiti-Pellie C. A method for estimating cancer risk in p53 mutation carriers. Cancer Detect Prev. 1994;18(3):171–178. [PubMed] [Google Scholar]
  15. Le Bihan C., Moutou C., Brugières L., Feunteun J., Bonaïti-Pellié C. ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet Epidemiol. 1995;12(1):13–25. doi: 10.1002/gepi.1370120103. [DOI] [PubMed] [Google Scholar]
  16. Li F. P., Fraumeni J. F., Jr, Mulvihill J. J., Blattner W. A., Dreyfus M. G., Tucker M. A., Miller R. W. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988 Sep 15;48(18):5358–5362. [PubMed] [Google Scholar]
  17. Lomax M. E., Barnes D. M., Gilchrist R., Picksley S. M., Varley J. M., Camplejohn R. S. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene. 1997 Apr 17;14(15):1869–1874. doi: 10.1038/sj.onc.1201133. [DOI] [PubMed] [Google Scholar]
  18. Lustbader E. D., Williams W. R., Bondy M. L., Strom S., Strong L. C. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet. 1992 Aug;51(2):344–356. [PMC free article] [PubMed] [Google Scholar]
  19. Malkin D., Jolly K. W., Barbier N., Look A. T., Friend S. H., Gebhardt M. C., Andersen T. I., Børresen A. L., Li F. P., Garber J. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 1992 May 14;326(20):1309–1315. doi: 10.1056/NEJM199205143262002. [DOI] [PubMed] [Google Scholar]
  20. Malkin D. p53 and the Li-Fraumeni syndrome. Biochim Biophys Acta. 1994 Dec 30;1198(2-3):197–213. doi: 10.1016/0304-419x(94)90014-0. [DOI] [PubMed] [Google Scholar]
  21. McIntyre J. F., Smith-Sorensen B., Friend S. H., Kassell J., Borresen A. L., Yan Y. X., Russo C., Sato J., Barbier N., Miser J. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994 May;12(5):925–930. doi: 10.1200/JCO.1994.12.5.925. [DOI] [PubMed] [Google Scholar]
  22. Scott R. J., Krummenacher F., Mary J. L., Weber W., Spycher M., Müller H. Vererbbare p53-Mutation bei einem Patienten mit Mehrfachtumoren: Bedeutung für die genetische Beratung. Schweiz Med Wochenschr. 1993 Jun 26;123(25):1287–1292. [PubMed] [Google Scholar]
  23. Speiser P., Gharehbaghi-Schnell E., Eder S., Haid A., Kovarík J., Nenutil R., Sauter G., Schneeberger C. H., Vojtesek B., Wiltschke C. H. A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br J Cancer. 1996 Jul;74(2):269–273. doi: 10.1038/bjc.1996.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Strong L. C., Williams W. R., Tainsky M. A. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol. 1992 Jan 15;135(2):190–199. doi: 10.1093/oxfordjournals.aje.a116271. [DOI] [PubMed] [Google Scholar]
  25. Toguchida J., Yamaguchi T., Dayton S. H., Beauchamp R. L., Herrera G. E., Ishizaki K., Yamamuro T., Meyers P. A., Little J. B., Sasaki M. S. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med. 1992 May 14;326(20):1301–1308. doi: 10.1056/NEJM199205143262001. [DOI] [PubMed] [Google Scholar]
  26. Varley J. M., Evans D. G., Birch J. M. Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer. 1997;76(1):1–14. doi: 10.1038/bjc.1997.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Varley J. M., McGown G., Thorncroft M., Cochrane S., Morrison P., Woll P., Kelsey A. M., Mitchell E. L., Boyle J., Birch J. M. A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene. 1996 Jun 6;12(11):2437–2442. [PubMed] [Google Scholar]
  28. Varley J. M., McGown G., Thorncroft M., James L. A., Margison G. P., Forster G., Evans D. G., Harris M., Kelsey A. M., Birch J. M. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet. 1999 Oct;65(4):995–1006. doi: 10.1086/302575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Varley J. M., McGown G., Thorncroft M., Santibanez-Koref M. F., Kelsey A. M., Tricker K. J., Evans D. G., Birch J. M. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 1997 Aug 1;57(15):3245–3252. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES